Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Optimizing Tumor-Infiltrating Lymphocyte (TIL) Harvest Site and Patient Selection With CD8-PET Imaging in Patients With

NCT: NCT07819474 · NOT_YET_RECRUITING

NCT IDNCT07819474
StatusNOT_YET_RECRUITING
Start Date2027-02-18
Completion2030-08-31
SponsorM.D. Anderson Cancer Center (OTHER)
First posted
Last updated

Brief Summary

To find out if the amount of CD8 immune cells at the place where TIL cells are collected is linked to how well a patient responds to treatment.

Frequently Asked Questions

What is Optimizing Tumor-Infiltrating Lymphocyte (TIL) Harvest Site and Patient Selection With CD8-PET Imaging in Patients With?

Optimizing Tumor-Infiltrating Lymphocyte (TIL) Harvest Site and Patient Selection With CD8-PET Imaging in Patients With is a clinical trial registered under NCT07819474. Current status: NOT_YET_RECRUITING.

What is the status of NCT07819474?

The current status of NCT07819474 (Optimizing Tumor-Infiltrating Lymphocyte (TIL) Harvest Site and Patient Selection With CD8-PET Imaging in Patients With) is: NOT_YET_RECRUITING.

When did Optimizing Tumor-Infiltrating Lymphocyte (TIL) Harvest Site and Patient Selection With CD8-PET Imaging in Patients With start?

Optimizing Tumor-Infiltrating Lymphocyte (TIL) Harvest Site and Patient Selection With CD8-PET Imaging in Patients With started on 2027-02-18.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑